Evidence map›Paper›PMID 29371592›Full record

ReviewCell death & disease2018

Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation.

Bo Peng, Yingzi Ming, Cheng Yang

Open access · goldAbstract readReview
In one paragraph

Review in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. TIGITFrontiers in immunology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. PD-L1International journal of molecular sciences · 2025
    Article
  11. Article
  12. Review
  13. Immune Landscape in Kidney Transplantation.Journal of inflammation research · 2025
    Review
  14. Article
  15. Article
  16. Ex vivo-generated human CD1cMolecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Bo PengTransplantation Center, The Third Xiangya Hospital, Central South University, Changsha Hunan, 410013, P. R. China.ORCID 0000-0003-4482-2885
Yingzi MingTransplantation Center, The Third Xiangya Hospital, Central South University, Changsha Hunan, 410013, P. R. China. myz_china@aliyun.com.
Cheng YangDepartment of Urology, Zhongshan Hospital; Shanghai Key Laboratory of Organ Transplantation, Fudan University, Shanghai, 200032, P. R. China. esuperyc@163.com.
Central South University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney transplantation is the optimal treatment for end-stage renal diseases. Although great improvement has been achieved, immune tolerance is still the Holy Grail that every organ transplant practitioner pursues. The role of B cells in transplantation has long been considered simply to serve as precursors of plasma cells, which produce alloantibodies and induce antibody-mediated rejection. Recent research indicates that a specialized subset of B cells plays an important role in immune regulation, which has been well demonstrated in autoimmune diseases, infections, and cancers. This category of regulatory B cells (Bregs) differs from conventional B cells, and they may help develop a novel immunomodulatory therapeutic strategy to achieve immune tolerance in transplantation. Here, we review the latest evidence regarding phenotypes, functions, and effectors of Bregs and discuss their diverse effects on kidney transplantation.

Indexed as

Immune ToleranceKidney TransplantationAnimalsBiomarkersB-Lymphocytes, RegulatoryGraft RejectionHumansModels, BiologicalBiomarkers

Identifiers

PMID29371592
PMCPMC5833552
OpenAlexW2794125535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.